


L1 HAS NO ANSWERS

L1 STR



VPA 10-1/2/3/4/5/6/7/8/9 U

NODE ATTRIBUTES:

NSPEC IS R AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

=> d his 13

(FILE 'REGISTRY' ENTERED AT 08:57:49 ON 08 JUN 2010)

L3 310 S L1 FUL

=> d his 14

(FILE 'CAPLUS' ENTERED AT 09:00:11 ON 08 JUN 2010)

L4 23 S L3

=> s 14 and py<=2005

26339918 PY<=2005

L5 17 L4 AND PY<=2005

=> d bib hitstr 1-17

L5 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:1241229 CAPLUS

DN 144:6818

TI Indazoles, benzothiazoles, 1,2-benzisoxazoles, 1,2-benzisothiazoles, and chromones as $\alpha 7$ nicotinic receptor agonists, their preparation, pharmaceutical compositions, and use in therapy

IN Xie, Wenge; Herbert, Brian; Schumacher, Richard A.; Ma, Jianguo; Nguyen, Truc Minh; Gauss, Carla Maria; Tehim, Ashok

PA Memory Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 143 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005111038	A2	20051124	WO 2005-US15937	20050506 <--
	WO 2005111038	A3	20060831		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005243147	A1	20051124	AU 2005-243147	20050506 <--
	CA 2565984	A1	20051124	CA 2005-2565984	20050506 <--
	US 20050272735	A1	20051208	US 2005-123219	20050506 <--
	US 7632831	B2	20091215		
	EP 1745046	A2	20070124	EP 2005-747486	20050506
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	BR 2005010212	A	20071016	BR 2005-10212	20050506
	JP 2007538011	T	20071227	JP 2007-511654	20050506
	RU 2386633	C2	20100420	RU 2006-143153	20050506
	MX 2006012880	A	20070126	MX 2006-12880	20061107
	IN 2006DN06854	A	20070831	IN 2006-DN6854	20061117
	ZA 2006009684	A	20080528	ZA 2006-9684	20061121
	NO 2006005622	A	20070202	NO 2006-5622	20061206
	KR 2007015607	A	20070205	KR 2006-725685	20061206
	CN 101124226	A	20080213	CN 2005-80023104	20070108
	US 20090325939	A1	20091231	US 2009-553538	20090903
PRAI	US 2004-568696P	P	20040507		
	US 2004-574712P	P	20040527		
	US 2004-626469P	P	20041110		
	US 2004-629469P	P	20041119		
	US 2005-123219	A1	20050506		
	WO 2005-US15937	W	20050506		
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT					
OS	CASREACT 144:6818; MARPAT 144:6818				
IT	869783-67-5P, N-[3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-1H-indazol-5-yl]pyrrolidine-1-carboxamide formate				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of heteroaryl-substituted diazabicyclo[3.2.2]nonanes as $\alpha 7$ nicotinic receptor agonists)				
RN	869783-67-5 CAPLUS				
CN	Formic acid, compd. with N-[3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-1H-indazol-5-yl]-1-pyrrolidinecarboxamide (1:1) (CA INDEX NAME)				
CM	1				
CRN	869783-66-4				
CMF	C20 H26 N6 O2				



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:1075795 CAPLUS

DN 143:347334

TI Preparation of quinuclidine indazole, benzothiazole, benzisothiazole and benzisoxazoles as ligands for the $\alpha 7$ nicotinic acetylcholine receptor

IN Xie, Wenge; Herbert, Brian; Schumacher, Richard; Nguyen, Truc Minh; Ma, Jianguo; Gauss, Carla Maria; Tehim, Ashok

PA Memory Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 300 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092890	A2	20051006	WO 2005-US10120	20050325 <--
	WO 2005092890	A3	20060202		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005227324	A1	20051006	AU 2005-227324	20050325 <--
	CA 2560741	A1	20051006	CA 2005-2560741	20050325 <--
	US 20050234095	A1	20051020	US 2005-89533	20050325 <--
	EP 1735306	A2	20061227	EP 2005-745169	20050325
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	CN 101001856	A	20070718	CN 2005-80016742	20050325

BR	2005008771	A	20070814	BR	2005-8771	20050325
JP	2007530590	T	20071101	JP	2007-505233	20050325
NZ	550534	A	20090731	NZ	2005-550534	20050325
MX	2006010852	A	20070116	MX	2006-10852	20060922
IN	2006DN06146	A	20091113	IN	2006-DN6146	20061020
ZA	2006008812	A	20080430	ZA	2006-8812	20061023
NO	2006004826	A	20061220	NO	2006-4826	20061024
KR	2007015406	A	20070202	KR	2006-722085	20061024
US	20100105677	A1	20100429	US	2009-631435	20091204
PRAI	US 2004-555951P	P	20040325			
	US 2004-616033P	P	20041006			
	US 2005-89533	A1	20050325			
	WO 2005-US10120	W	20050325			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:347334; MARPAT 143:347334

IT 865886-33-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinuclidine indazole, benzothiazole, benzoisothiazole and benzisoxazole derivs. as ligands for $\alpha 7$ nACh receptor subunit)

RN 865886-33-5 CAPLUS


CN Formic acid, compd. with N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-[(1-pyrrolidinylcarbonyl)amino]-1H-indazole-3-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 865886-32-4

CMF C20 H26 N6 O2

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:902862 CAPLUS

DN 143:248381

TI Preparation of indazole compounds as MMP-9 inhibitors
 IN Takemiya, Akihiro; Nakajo, Masahiro; Oshima, Hisae; Yanagi, Tomotaka;
 Mochizuki, Mami; Nakamura, Hideo
 PA Mitsubishi Pharma Corporation, Japan
 SO PCT Int. Appl., 147 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005077912	A1	20050825	WO 2005-JP1996	20050210 <--
	W:				AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
	RW:				BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
	EP 1714961	A1	20061025	EP 2005-710048	20050210
	R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
	US 20070173537	A1	20070726	US 2007-589130	20070116
PRAI	JP 2004-35565	A	20040212		
	WO 2005-JP1996	W	20050210		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 143:248381

IT 863109-28-8P 863109-78-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indazole compds. as MMP-9 inhibitors for treatment of cancer)


RN 863109-28-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)



RN 863109-78-8 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-(4-fluorophenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




IT	863109-29-9P	863109-30-2P	863109-31-3P
	863109-32-4P	863109-33-5P	863109-34-6P
	863109-35-7P	863109-36-8P	863109-37-9P
	863109-38-0P	863109-39-1P	863109-40-4P
	863109-41-5P	863109-42-6P	863109-43-7P
	863109-44-8P	863109-45-9P	863109-46-0P
	863109-47-1P	863109-48-2P	863109-49-3P
	863109-50-6P	863109-51-7P	863109-52-8P
	863109-53-9P	863109-54-0P	863109-55-1P
	863109-56-2P	863109-57-3P	863109-58-4P
	863109-59-5P	863109-60-8P	863109-61-9P
	863109-62-0P	863109-63-1P	863109-65-3P
	863109-66-4P	863109-67-5P	863109-68-6P
	863109-69-7P	863109-70-0P	863109-71-1P
	863109-72-2P	863109-73-3P	863109-74-4P
	863109-75-5P	863109-76-6P	863109-77-7P
	863109-79-9P	863109-80-2P	863109-81-3P
	863109-82-4P	863109-83-5P	863109-84-6P
	863109-85-7P	863109-86-8P	863109-87-9P
	863109-88-0P	863109-89-1P	863109-90-4P
	863109-91-5P	863109-92-6P	863109-93-7P
	863109-95-9P	863109-96-0P	863109-97-1P
	863109-98-2P	863109-99-3P	863110-00-3P
	863110-01-4P	863110-02-5P	863110-03-6P
	863110-04-7P	863110-05-8P	863110-06-9P
	863110-07-0P	863110-08-1P	863110-09-2P
	863110-10-5P	863110-11-6P	863110-12-7P
	863110-13-8P	863110-14-9P	863110-15-0P
	863110-16-1P	863110-17-2P	863110-18-3P
	863110-19-4P	863110-20-7P	863110-21-8P
	863110-22-9P	863110-23-0P	863110-24-1P
	863110-25-2P	863110-26-3P	863110-27-4P
	863110-28-5P	863110-29-6P	863110-30-9P
	863110-32-1P	863110-33-2P	863110-34-3P
	863110-35-4P	863110-36-5P	863110-37-6P
	863110-38-7P	863110-39-8P	863110-40-1P
	863110-41-2P	863110-42-3P	863110-43-4P
	863110-44-5P	863110-45-6P	863110-46-7P
	863110-47-8P	863110-48-9P	863110-49-0P
	863110-50-3P	863110-51-4P	863110-52-5P
	863110-53-6P	863110-54-7P	863110-55-8P
	863110-56-9P	863110-57-0P	863110-58-1P
	863110-59-2P	863110-61-6P	863110-62-7P
	863110-63-8P	863110-64-9P	863110-65-0P
	863110-66-1P	863110-67-2P	863110-68-3P
	863110-69-4P	863110-70-7P	863110-71-8P
	863110-73-0P	863110-74-1P	863110-75-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazole compds. as MMP-9 inhibitors for treatment of cancer)


RN 863109-29-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-phenyl- (CA INDEX NAME)




RN 863109-30-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 863109-31-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-32-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-fluorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-33-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-34-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 863109-35-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 863109-36-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-fluoro-3-(trifluoromethyl)phenyl]-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-37-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-[4-methyl-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 863109-38-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-(3-fluorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-39-1 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(3,5-difluorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-40-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-(3-pyridinyl)- (CA INDEX NAME)



RN 863109-41-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(5-chloro-2-thienyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-42-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(3-chloro-4-fluorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-43-7 CAPLUS
 CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-(3,4,5-

trifluorophenyl)- (CA INDEX NAME)




RN 863109-44-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chloro-3-fluorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-45-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-fluoro-2-(trifluoromethyl)phenyl]-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-46-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(5-bromo-3-chloro-2-fluorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-47-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-chloro-2-fluorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-48-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3,4-dichlorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-49-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-chloro-5-fluorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-50-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chloro-3-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-51-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-chlorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-52-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-(2-naphthalenyl)-
(CA INDEX NAME)




RN 863109-53-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2-chloro-4-pyridinyl)-4-hydroxy-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863109-54-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,3-benzodioxol-5-yl)-4-hydroxy-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863109-55-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-(3-methylphenyl)-
(CA INDEX NAME)




RN 863109-56-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-cyanophenyl)-4-hydroxy-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863109-57-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-hydroxy-N-1H-indazol-3-yl-4-[3-(methylthio)phenyl]- (CA INDEX NAME)




RN 863109-58-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-ethylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-59-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-60-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,5-dichlorophenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-61-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-62-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-63-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-chloro-5-(trifluoromethyl)phenyl]-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-65-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-chloro-3-[(diethylamino)methyl]phenyl]-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-66-4 CAPLUS


CN 1-Piperidinecarboxamide, 4-cyano-N-1H-indazol-3-yl-4-phenyl- (CA INDEX NAME)




RN 863109-67-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-cyano-4-(4-fluorophenyl)-N-1H-indazol-3-yl-
 (CA INDEX NAME)




RN 863109-68-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-cyano-N-1H-indazol-3-yl-4-(2-methoxyphenyl)-
 (CA INDEX NAME)



RN 863109-69-7 CAPLUS
 CN 1-Piperidinecarboxamide, 4-cyano-N-1H-indazol-3-yl-4-[4-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)




RN 863109-70-0 CAPLUS
 CN 1-Piperidinecarboxamide, 4-cyano-N-1H-indazol-3-yl-4-[3-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)




RN 863109-71-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-cyano-4-(2-fluorophenyl)-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863109-72-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-chloro-3-(trifluoromethyl)phenyl]-4-cyano-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863109-73-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-cyano-4-[3-fluoro-5-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863109-74-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(5-bromo-2-thienyl)-4-cyano-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863109-75-5 CAPLUS


CN 1-Piperidinecarboxamide, 4-cyano-4-(3,5-difluorophenyl)-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863109-76-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(4-bromo-2-chlorophenyl)-4-cyano-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-77-7 CAPLUS
 CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-1H-indazol-3-yl-4-phenyl- (CA INDEX NAME)



RN 863109-79-9 CAPLUS
 CN 1(2H)-Pyridinecarboxamide, 4-(4-chlorophenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-80-2 CAPLUS
 CN 1(2H)-Pyridinecarboxamide, 4-(2-fluorophenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-81-3 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-(3-chloro-4-fluorophenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-82-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-1H-indazol-3-yl-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 863109-83-5 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-(3-fluorophenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-84-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-(2,3-difluorophenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-85-7 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-(2,4-difluorophenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-86-8 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-(5-chloro-2-thienyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-87-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-1H-indazol-3-yl-4-(3-methyl-2-thienyl)- (CA INDEX NAME)




RN 863109-88-0 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-1H-indazol-3-yl-4-(2-thienyl)- (CA INDEX NAME)




RN 863109-89-1 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-1H-indazol-3-yl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 863109-90-4 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-(3,4-dimethoxyphenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-91-5 CAPLUS
 CN 1(2H)-Pyridinecarboxamide, 4-[3-(dimethylamino)phenyl]-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-92-6 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide, 1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-93-7 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide, 1,3,4,9-tetrahydro-N-1H-indazol-3-yl-9-methyl- (CA INDEX NAME)




RN 863109-95-9 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide, 1,3,4,9-tetrahydro-N-1H-indazol-3-yl-9-(2-methoxyethyl)- (CA INDEX NAME)



RN 863109-96-0 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 1,3,4,9-tetrahydro-N-1H-indazol-3-yl-9-[2-(4-morpholinyl)ethyl]- (CA
 INDEX NAME)




RN 863109-97-1 CAPLUS
 CN 2H-Pyrido[4,3-b]indole-2-carboxamide,
 1,3,4,5-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863109-98-2 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,


1,3,4,9-tetrahydro-N-1H-indazol-3-yl-6-(trifluoromethyl)- (CA INDEX NAME)




RN 863109-99-3 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
6-fluoro-1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-00-3 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
7-fluoro-1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-01-4 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
6-chloro-1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-02-5 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 1,3,4,9-tetrahydro-N-1H-indazol-3-yl-6-methoxy- (CA INDEX NAME)




RN 863110-03-6 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 1,3,4,9-tetrahydro-6-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-04-7 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 7-chloro-1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-05-8 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
1,3,4,9-tetrahydro-N-1H-indazol-3-yl-7-(trifluoromethyl)- (CA INDEX NAME)




RN 863110-06-9 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
5-fluoro-1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-07-0 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
5-chloro-1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-08-1 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
1,3,4,9-tetrahydro-N-1H-indazol-3-yl-8-methyl- (CA INDEX NAME)




RN 863110-09-2 CAPLUS
 CN [1]Benzo[thieno[2,3-c]pyridine-2(1H)-carboxamide,
 3,4-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-10-5 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 1,3,4,9-tetrahydro-N-1H-indazol-3-yl-6-methyl- (CA INDEX NAME)




RN 863110-11-6 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 7-chloro-6-fluoro-1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-12-7 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 7-chloro-1,3,4,9-tetrahydro-N-1H-indazol-3-yl-6-(trifluoromethyl)- (CA
 INDEX NAME)




RN 863110-13-8 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(4-fluorophenyl)-N-1H-indazol-3-yl- (CA INDEX
 NAME)




RN 863110-14-9 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2-fluorophenyl)-N-1H-indazol-3-yl- (CA INDEX
 NAME)




RN 863110-15-0 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2,4-difluorophenyl)-N-1H-indazol-3-yl- (CA
 INDEX NAME)




RN 863110-16-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-(2-thienyl)- (CA INDEX NAME)




RN 863110-17-2 CAPLUS
 CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-[5-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 863110-18-3 CAPLUS
 CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 863110-19-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(5-fluoro-2-pyrimidinyl)-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-20-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)




RN 863110-21-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-chloro-4-fluorophenyl)-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863110-22-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-[4-chloro-3-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-23-0 CAPLUS

CN 1-Piperazinecarboxamide, 4-[4-fluoro-3-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-24-1 CAPLUS

CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-[4-methoxy-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 863110-25-2 CAPLUS


CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-[4-(trifluoromethyl)-2-thiazolyl]- (CA INDEX NAME)




RN 863110-26-3 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-fluoro-5-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-27-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(3,4-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-28-5 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-chloro-5-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-29-6 CAPLUS
 CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 863110-30-9 CAPLUS
 CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-[2-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)




RN 863110-32-1 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2-cyanophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-33-2 CAPLUS
 CN 2H-[1]Benzopyrano[3,4-c]pyridine-3(4H)-carboxamide,
 1,5-dihydro-N-1H-indazol-3-yl-5-oxo- (CA INDEX NAME)




RN 863110-34-3 CAPLUS
 CN Benzo[c][2,7]naphthyridine-3(2H)-carboxamide,
 1,4,5,6-tetrahydro-N-1H-indazol-3-yl-5-oxo- (CA INDEX NAME)




RN 863110-35-4 CAPLUS
 CN Pyrazino[1,2-a]benzimidazole-2(1H)-carboxamide,
 3,4-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-36-5 CAPLUS
 CN Pyrazino[1,2-a]indole-2(1H)-carboxamide, 3,4-dihydro-N-1H-indazol-3-yl-
 (CA INDEX NAME)




RN 863110-37-6 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 1,3,4,9-tetrahydro-N-1H-indazol-3-yl-1-(4-morpholinylmethyl)- (CA INDEX
 NAME)




RN 863110-38-7 CAPLUS
 CN 2H-Pyrido[3,4-b]indole-2-carboxamide,
 1-[(dimethylamino)methyl]-1,3,4,9-tetrahydro-N-1H-indazol-3-yl- (CA INDEX
 NAME)




RN 863110-39-8 CAPLUS
 CN Benzo[c][1,7]naphthyridine-3(2H)-carboxamide,
 1,4,5,6-tetrahydro-N-1H-indazol-3-yl-6-oxo- (CA INDEX NAME)




RN 863110-40-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-1H-indazol-3-yl-4-phenyl- (CA INDEX NAME)




RN 863110-41-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2-fluorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-42-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-1H-indazol-3-yl-4-[3-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)




RN 863110-43-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-1H-indazol-3-yl-3-phenyl- (CA INDEX NAME)




RN 863110-44-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-1H-indazol-3-yl-4-(4-morpholinylcarbonyl)-4-phenyl- (CA INDEX NAME)




RN 863110-45-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-1H-indazol-3-yl-4-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



RN 863110-46-7 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[4-chloro-3-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl-4-methoxy- (CA INDEX NAME)




RN 863110-47-8 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[4-chloro-3-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl-3-methyl- (CA INDEX NAME)




RN 863110-48-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 5,6-dihydro-N-1H-indazol-3-yl-3-methyl-4-phenyl-4-chloro-3-(trifluoromethyl)- (CA INDEX NAME)




RN 863110-49-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-N-1H-indazol-3-yl-N-methyl- (CA INDEX NAME)




RN 863110-50-3 CAPLUS

CN 1-Piperazinecarboxamide, 4-[4-chloro-3-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl-N-methyl- (CA INDEX NAME)




RN 863110-51-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-(4-fluorophenyl)-3,6-dihydro-N-1H-indazol-3-yl-N-methyl- (CA INDEX NAME)




RN 863110-52-5 CAPLUS

CN 1-(2H)-Pyridinecarboxamide, N-3-buten-1-yl-4-(4-fluorophenyl)-3,6-dihydro-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-53-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-chloro-3-(trifluoromethyl)phenyl]-N-1H-indazol-3-yl-4-methyl- (CA INDEX NAME)




RN 863110-54-7 CAPLUS

CN 1-Piperazinecarboxamide, N-1H-indazol-3-yl-4-(3-pyridinyl)- (CA INDEX NAME)




RN 863110-55-8 CAPLUS

CN 1-Piperidinecarboxamide, 3-(3-fluorophenyl)-3-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-56-9 CAPLUS

CN 1-Pyrrolidinecarboxamide, 3-(4-fluorophenyl)-3-hydroxy-N-1H-indazol-3-yl-
(CA INDEX NAME)




RN 863110-57-0 CAPLUS

CN 1-Piperidinecarboxamide, 3-[4-chloro-3-(trifluoromethyl)phenyl]-3-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-58-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-(2-methylphenyl)-
(CA INDEX NAME)




RN 863110-59-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2-fluoro-5-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-61-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-chloro-2-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-62-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-chloro-4-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-63-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-fluoro-4-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-64-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-fluoro-2-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-65-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(5-fluoro-2-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-66-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-fluoro-3-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-67-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-(4-methylphenyl)- (CA INDEX NAME)




RN 863110-68-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-fluoro-5-methylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-69-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,5-dimethylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-70-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-[2-methyl-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 863110-71-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-1H-indazol-3-yl-4-[2-methyl-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 863110-73-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3,4-dimethylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 863110-74-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3,5-dimethylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)



RN 863110-75-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dimethylphenyl)-4-hydroxy-N-1H-indazol-3-yl- (CA INDEX NAME)




IT 863111-33-5P 863111-34-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indazole compds. as MMP-9 inhibitors for treatment of cancer)


RN 863111-33-5 CAPLUS

CN 1H-Indazole-1-carboxylic acid, 3-[[[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 863111-34-6 CAPLUS

CN 1H-Indazole-1-carboxylic acid, 3-[[[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:732625 CAPLUS
DN 143:211907
TI Preparation of indazoles as inhibitors of hormone-sensitive lipase (HSL).
IN Zoller, Gerhard; Petry, Stefan; Mueller, Guenter; Heuer, Hubert;
Baringhaus, Karl-Heinz
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005073199	A1	20050811	WO 2005-EP365	20050115 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004005172	A1	20050818	DE 2004-102004005172	20040202 <--
	AU 2005209366	A1	20050811	AU 2005-209366	20050115 <--
	CA 2554524	A1	20050811	CA 2005-2554524	20050115 <--
	EP 1713779	A1	20061025	EP 2005-700954	20050115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	CN 1914180	A	20070214	CN 2005-80003798	20050115
	BR 2005007370	A	20070710	BR 2005-7370	20050115
	JP 2007519649	T	20070719	JP 2006-549989	20050115
	SG 149891	A1	20090227	SG 2009-705	20050115
	RU 2370491	C2	20091020	RU 2006-131564	20050115
	NZ 548872	A	20100430	NZ 2005-548872	20050115
	US 20050197348	A1	20050908	US 2005-42565	20050125 <--
	US 7528155	B2	20090505		
	ZA 2006005311	A	20071031	ZA 2006-5311	20060627
	MX 2006008406	A	20061009	MX 2006-8406	20060726
	KR 2006128958	A	20061214	KR 2006-715071	20060726
	IN 2006CN02819	A	20070608	IN 2006-CN2819	20060801
	NO 2006003925	A	20060901	NO 2006-3925	20060901
	US 20090215824	A1	20090827	US 2009-431010	20090428
PRAI	DE 2004-102004005172	A	20040202		
	US 2004-582669P	P	20040624		
	WO 2005-EP365	W	20050115		
	US 2005-42565	A1	20050125		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS CASREACT 143:211907; MARPAT 143:211907

IT 862273-39-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazoles as inhibitors of hormone-sensitive lipases)


RN 862273-39-0 CAPLUS
CN 1-Piperidinecarboxamide, N-1H-indazol-3-yl-4-methyl- (CA INDEX NAME)



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:450974 CAPLUS
DN 142:481963
TI Preparation of used azabicyclic compounds that inhibit vanilloid receptor
subtype 1 (VR1) receptor
IN Lee, Chih-Hung; Bayburt, Erol K.; DiDomenico, Stanley; Drizin, Irene;
Gomtsyan, Arthur R.; Koenig, John R.; Perner, Richard J.; Schmidt, Robert
G.; Turner, Sean C.; Jinkerson, Tammie K.; Zheng, Guo Zhu
PA USA
SO U.S. Pat. Appl. Publ., 94 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050113576	A1	20050526	US 2004-911019	20040804 <--
PRAI	US 2003-492528P	P	20030805		
OS	CASREACT 142:481963; MARPAT 142:481963				
IT	735331-11-0P, N-(1-Methyl-1H-indazol-4-yl)-4-[4-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamidehydrochloride 735331-30-3P, N-(1-Methyl-1H-indazol-4-yl)-4-[4-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fused azabicyclic compds. that inhibit vanilloid subtype 1 (VR1) receptor)				
RN	735331-11-0 CAPLUS				
CN	1-Piperazinecarboxamide, N-(1-methyl-1H-indazol-4-yl)-4-[4-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)				



RN 735331-30-3 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-methyl-1H-indazol-4-yl)-4-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:34603 CAPLUS

DN 142:134589

TI Preparation of indazole derivatives for treating or preventing diseases associated with protein kinases

IN Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.; Buhr, Chris A.; Albers, Ronald; Sapienza, John; Plantevin, Veronique; Chao, Qi; Sahasrabudhe, Kiran; Ferri, Rachel; Narla, Rama K.

PA USA

SO U.S. Pat. Appl. Publ., 240 pp., Cont.-in-part of U.S. Ser. No. 414,839.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050009876	A1	20050113	US 2003-718185	20031119 <--
	US 20020103229	A1	20020801	US 2001-910950	20010723 <--
	US 6897231	B2	20050524		
	US 20040127536	A1	20040701	US 2003-414839	20030416 <--
	US 7211594	B2	20070501		
	US 20070060616	A1	20070315	US 2006-512836	20060830
PRAI	US 2000-221799P	P	20000731		
	US 2001-910950	A2	20010723		
	US 2003-414839	A2	20030416		
	US 2003-718185	A1	20031119		

OS MARPAT 142:134589

IT 395099-94-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]morpholine-4-carboxamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazole derivs. for treating or preventing diseases associated

with protein kinases)

RN 395099-94-2 CAPLUS

CN 4-Morpholinecarboxamide, N-[3-(4-fluorophenyl)-1H-indazol-5-yl]- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L5 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:652634 CAPLUS

DN 141:174087

TI Preparation of fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1)

IN Lee, Chih-Hung; Bayburt, Erol K.; Didomenico, Stanley; Drizin, Irene; Gomtsyan, Arthur R.; Koenig, John R.; Perner, Richard J.; Schmidt, Robert G.; Turner, Sean C.; White, Tammie K.; Zheng, Guo Zhu

PA Abbott Laboratories, USA

SO U.S. Pat. Appl. Publ., 93 pp., Cont.-in-part of U.S. Ser. No. 364,210.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 3


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	US 20040157849	A1	20040812	US 2003-634678	20030805 <--
	US 6933311	B2	20050823		
	US 20030158198	A1	20030821	US 2003-364210	20030211 <--
	US 7074805	B2	20060711		
	AU 2004265306	A1	20050224	AU 2004-265306	20040804 <--
	CA 2534542	A1	20050224	CA 2004-2534542	20040804 <--
	WO 2005016890	A1	20050224	WO 2004-US25109	20040804 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1660455	A1	20060531	EP 2004-780017	20040804
	EP 1660455	B1	20081015		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004013305	A	20061010	BR 2004-13305	20040804
	CN 1863777	A	20061115	CN 2004-80028884	20040804
	JP 2007501246	T	20070125	JP 2006-522680	20040804
	AT 411293	T	20081015	AT 2004-780017	20040804
	ES 2315704	T3	20090401	ES 2004-780017	20040804
	MX 2006001396	A	20070213	MX 2006-1396	20060203
	ZA 2006001022	A	20070530	ZA 2006-1022	20060203
	KR 2007026291	A	20070308	KR 2006-702563	20060206
	IN 2006MN00238	A	20070629	IN 2006-MN238	20060301
PRAI	US 2003-364210	A2	20030211		
	US 2002-358220P	P	20020220		
	US 2003-634678	A	20030805		
	WO 2004-US25109	W	20040804		
OS	MARPAT 141:174087				
IT	735331-11-0P, N-(1-Methyl-1H-indazol-4-yl)-4-[4- (trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide hydrochloride 735331-30-3P, N-(1-Methyl-1H-indazol-4-yl)-4-[4-(trifluoromethyl)- 2-pyridinyl]piperazine-1-carboxamide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fused azabicyclic compds. that inhibit vanilloid receptor subtype 1 (VR1))				
RN	735331-11-0 CAPLUS				
CN	1-Piperazinecarboxamide, N-(1-methyl-1H-indazol-4-yl)-4-[4- (trifluoromethyl)-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)				



RN 735331-30-3 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-methyl-1H-indazol-4-yl)-4-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:610080 CAPLUS

DN 141:140438

TI Preparation of aminoindazoles as protein Tau phosphorylation inhibitors, their drugs and pharmaceutical compositions containing them for treatment, in particular, of central and peripheral nervous system diseases

IN Lesuisse, Dominique; Dutruc-Rosset, Gilles; Halley, Franck; Babin, Didier; Rooney, Thomas; Tiraboschi, Gilles

PA Aventis Pharma S.A., Fr.
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004062662	A1	20040729	WO 2003-FR2634	20030903 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2848554	A1	20040618	FR 2002-15720	20021212 <--
	CA 2507948	A1	20040729	CA 2003-2507948	20030903 <--
	AU 2003278250	A1	20040810	AU 2003-278250	20030903 <--
	EP 1572200	A1	20050914	EP 2003-769560	20030903 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016606	A	20051011	BR 2003-16606	20030903 <--
	JP 2006516266	T	20060629	JP 2005-512867	20030903
	RU 2339624	C2	20081127	RU 2005-121897	20030903
	NZ 541193	A	20090131	NZ 2003-541193	20030903
	MX 2005005554	A	20050726	MX 2005-5554	20050525 <--
	HR 2005000533	A2	20061130	HR 2005-533	20050610
	IN 2005CN01204	A	20070622	IN 2005-CN1204	20050610
	NO 2005003356	A	20050711	NO 2005-3356	20050711 <--
PRAI	FR 2002-15720	A	20021212		
	US 2003-444630P	P	20030204		
	WO 2003-FR2634	W	20030903		

OS MARPAT 141:140438

IT 727425-83-4P, Piperidine-1-carboxylic acid


N-[6,7-difluoro-5-phenyl-1-[[2-(trimethylsilyl)ethoxy)methyl]-1H-indazol-3-yl]amide 727425-85-6P, Pyrrolidine-1-carboxylic acid
 N-[6,7-difluoro-5-phenyl-1-[[2-(trimethylsilyl)ethoxy)methyl]-1H-indazol-3-yl]amide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aminoindazoles as protein Tau phosphorylation inhibitors for treating central and peripheral nervous system diseases)


RN 727425-83-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[6,7-difluoro-5-phenyl-1-[[2-(trimethylsilyl)ethoxy)methyl]-1H-indazol-3-yl]- (CA INDEX NAME)




RN 727425-85-6 CAPLUS


CN 1-Pyrrolidinecarboxamide, N-[6,7-difluoro-5-phenyl-1-[[2-(trimethylsilyl)ethoxy)methyl]-1H-indazol-3-yl]- (CA INDEX NAME)



IT 727425-81-2P, Piperidine-1-carboxylic acid
 N-(6,7-difluoro-5-phenyl-1H-indazol-3-yl)amide 727425-84-5P,
 Pyrrolidine-1-carboxylic acid N-(6,7-difluoro-5-phenyl-1H-indazol-3-yl)amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protein Tau inhibitor; preparation of aminoindazoles as protein Tau phosphorylation inhibitors for treating central and peripheral nervous system diseases)
 RN 727425-81-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-(6,7-difluoro-5-phenyl-1H-indazol-3-yl)- (CA INDEX NAME)



RN 727425-84-5 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-(6,7-difluoro-5-phenyl-1H-indazol-3-yl)- (CA INDEX NAME)




OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:533982 CAPLUS
 DN 141:89085
 TI Preparation of indazole derivatives as JNK enzyme inhibitors
 IN Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.; Buhr, Chris A.; Albers, Ronald; Sapienza, John; Plantevin, Veronique; Chao, Qi;

Sahasrabudhe, Kiran; Ferri, Rachel
 PA Signal Pharmaceuticals, LLC, USA
 SO U.S. Pat. Appl. Publ., 275 pp., Cont.-in-part of U.S. Ser. No. 910,950.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20040127536	A1	20040701	US 2003-414839	20030416	<--
	US 7211594	B2	20070501			
	US 20020103229	A1	20020801	US 2001-910950	20010723	<--
	US 6897231	B2	20050524			
	US 20040077877	A1	20040422	US 2003-673121	20030926	<--
	US 7220771	B2	20070522			
	US 20050009876	A1	20050113	US 2003-718185	20031119	<--
AU	2004232981	A1	20041104	AU 2004-232981	20040416	<--
CA	2522682	A1	20041104	CA 2004-2522682	20040416	<--
WO	2004094388	A2	20041104	WO 2004-US11958	20040416	<--
WO	2004094388	A3	20041209			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP	1618093	A2	20060125	EP 2004-750298	20040416	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR	2004009417	A	20060425	BR 2004-9417	20040416	
JP	2006523721	T	20061019	JP 2006-513108	20040416	
ZA	2005008359	A	20090225	ZA 2005-8359	20040416	
US	20050107457	A1	20050519	US 2004-462	20041130	<--
US	7208513	B2	20070424			
MX	2005010958	A	20060130	MX 2005-10958	20051012	
US	20070060616	A1	20070315	US 2006-512836	20060830	
PRAI	US 2000-221799P	P	20000731			
	US 2001-910950	A2	20010723			
	US 2003-414839	A2	20030416			
	US 2003-718185	A1	20031119			
	WO 2004-US11958	W	20040416			
OS	MARPAT 141:89085					
IT	395099-94-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]morpholine-4-carboxamide					
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)					
	(preparation of indazole derivs. as JNK enzyme inhibitors)					
RN	395099-94-2 CAPLUS					
CN	4-Morpholinecarboxamide, N-[3-(4-fluorophenyl)-1H-indazol-5-yl]- (CA INDEX NAME)					



OSC.G 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (67 CITINGS)
 RE.CNT 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:220319 CAPLUS

DN 140:253562

TI Preparation of aminoindazoles as protein Tau phosphorylation inhibitors,
 their drugs and pharmaceutical compositions containing them for treatment,
 in particular, of central and peripheral nervous system diseases

IN Lesuisse, Dominique; Dutruc-Rosset, Gilles; Halley, Franck; Babin, Didier;
 Rooney, Thomas

PA Aventis Pharma S.A., Fr.

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2


DT Patent

LA French


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004022544	A1	20040318	WO 2003-FR2633	20030903 <--	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	FR 2844267	A1	20040312	FR 2002-10962	20020905 <--	
	FR 2844267	B1	20080215			
	CA 2497351	A1	20040318	CA 2003-2497351	20030903 <--	
	AU 2003278249	A1	20040329	AU 2003-278249	20030903 <--	
	EP 1537087	A1	20050608	EP 2003-769559	20030903 <--	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	BR 2003014098	A	20050719	BR 2003-14098	20030903 <--	
	JP 2006503824	T	20060202	JP 2004-533563	20030903	
	NZ 539193	A	20080430	NZ 2003-539193	20030903	
	RU 2378259	C2	20100110	RU 2005-109561	20030903	
	MX 2005001807	A	20050419	MX 2005-1807	20050215 <--	
	HR 2005000217	A2	20060630	HR 2005-217	20050304	
	IN 2005CN00325	A	20070330	IN 2005-CN325	20050304	
	IN 218796	A1	20080523			
	NO 2005001645	A	20050519	NO 2005-1645	20050404 <--	
PRAI	FR 2002-10962	A	20020905			


US 2002-419965P P 20021022
 WO 2003-FR2633 W 20030903
 OS MARPAT 140:253562
 IT 670749-71-0P, Pyrrolidine-1-carboxylic acid
 N-(6-chloro-5-phenyl-1H-indazol-3-yl)amide 670749-77-6P,
 Piperidine-1-carboxylic acid N-(6-chloro-5-phenyl-1H-indazol-3-yl)amide
 670749-84-5P, 2,5-Dimethylpyrrolidine-1-carboxylic acid
 N-(6-chloro-5-phenyl-1H-indazol-3-yl)amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (inhibitor of protein Tau phosphorylation; preparation of aminoindazoles as
 protein Tau phosphorylation inhibitors for treatment of central and
 peripheral nervous system diseases)
 RN 670749-71-0 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-(6-chloro-5-phenyl-1H-indazol-3-yl)- (CA
 INDEX NAME)



RN 670749-77-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-(6-chloro-5-phenyl-1H-indazol-3-yl)- (CA INDEX
 NAME)



RN 670749-84-5 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-(6-chloro-5-phenyl-1H-indazol-3-yl)-2,5-
 dimethyl- (CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:931339 CAPLUS

DN 140:5044
 TI Preparation of 3-aminoindazole derivatives as kinase inhibitors
 IN Martina, Katia; Brill, Wolfgang
 PA Pharmacia Italia S.P.A., Italy
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003097610	A1	20031127	WO 2003-EP4862	20030508 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2486101	A1	20031127	CA 2003-2486101	20030508 <--
	CA 2486101	C	20090707		
	AU 2003227741	A1	20031202	AU 2003-227741	20030508 <--
	EP 1506176	A1	20050216	EP 2003-725180	20030508 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003011291	A	20050329	BR 2003-11291	20030508 <--
	JP 2005534635	T	20051117	JP 2004-505343	20030508 <--
	MX 2004011417	A	20050214	MX 2004-11417	20041117 <--
	US 20060106083	A1	20060518	US 2004-990866	20041117
	US 7632854	B2	20091215		
PRAI	US 2002-381092P	P	20020517		
	WO 2003-EP4862	W	20030508		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS CASREACT 140:5044; MARPAT 140:5044

IT 627857-61-8P 627857-72-1P 627857-76-5P
 627857-84-5P 627857-87-8P 627857-95-8P
 627857-99-2P 627858-08-6P 627858-16-6P
 627858-20-2P 627858-25-7P 627858-35-9P
 627858-36-0P 627858-40-6P 627858-44-0P
 627858-46-2P 627858-47-3P 627858-48-4P
 627858-50-8P 627858-54-2P 627858-56-4P
 627858-57-5P 627858-58-6P 627858-62-2P
 627858-66-6P 627858-68-8P 627858-69-9P
 627858-70-2P 627858-74-6P 627858-78-0P
 627858-80-4P 627858-81-5P 627858-82-6P
 627858-86-0P 627858-90-6P 627858-92-8P
 627858-94-0P 627858-95-1P 627858-99-5P
 627859-03-4P 627859-05-6P 627859-06-7P
 627859-10-3P 627859-16-9P 627859-17-0P
 627859-18-1P 627859-19-2P 627859-22-7P
 627859-24-9P 627859-26-1P 627859-27-2P
 627859-28-3P 627859-29-4P 627859-31-8P
 627859-36-3P 627859-38-5P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (preparation of 3-aminoindazole derivs. as kinase inhibitors)


RN 627857-61-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627857-72-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627857-76-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627857-84-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627857-87-8 CAPLUS


CN 1-Piperazinecarboxamide, N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627857-95-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-(4-methylphenyl)-1H-indazol-3-yl]- (CA
INDEX NAME)




RN 627857-99-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[6-(4-methylphenyl)-1H-indazol-3-yl]- (CA
INDEX NAME)




RN 627858-08-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[6-(2-methoxyphenyl)-1H-indazol-3-yl]- (CA
INDEX NAME)



RN 627858-16-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-(3-methylphenyl)-1H-indazol-3-yl]- (CA
INDEX NAME)




RN 627858-20-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[6-(3-methylphenyl)-1H-indazol-3-yl]- (CA
INDEX NAME)




RN 627858-25-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627858-35-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]-4-methyl-
(CA INDEX NAME)




RN 627858-36-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]-4-methyl-
(CA INDEX NAME)




RN 627858-40-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627858-44-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-46-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-47-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]-4-methyl- (CA INDEX NAME)




RN 627858-48-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]-4-methyl- (CA INDEX NAME)




RN 627858-50-8 CAPLUS


CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-54-2 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-56-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-57-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-methyl-N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-58-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-methyl-N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-62-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-66-6 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-68-8 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-69-9 CAPLUS
 CN 1-Piperidinecarboxamide, 4-methyl-N-[6-(4-methylphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)



RN 627858-70-2 CAPLUS
 CN 1-Piperazinecarboxamide, 4-methyl-N-[6-(4-methylphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-74-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(4-methylphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-78-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[6-(4-methylphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-80-4 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-N-[6-(4-methylphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627858-81-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2-methoxyphenyl)-1H-indazol-3-yl]-4-methyl- (CA INDEX NAME)




RN 627858-82-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[6-(2-methoxyphenyl)-1H-indazol-3-yl]-4-methyl- (CA INDEX NAME)




RN 627858-86-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(2-methoxyphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627858-90-6 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[6-(2-methoxyphenyl)-1H-indazol-3-yl]- (CA
INDEX NAME)




RN 627858-92-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-N-[6-(2-methoxyphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627858-94-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-N-[6-(3-methylphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627858-95-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-methyl-N-[6-(3-methylphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627858-99-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[6-(3-methylphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627859-03-4 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[6-(3-methylphenyl)-1H-indazol-3-yl]- (CA
INDEX NAME)




RN 627859-05-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-N-[6-(3-methylphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627859-06-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-4-
methyl- (CA INDEX NAME)




RN 627859-10-3 CAPLUS


CN 1-Piperidinecarboxamide, N-[6-[3-(acetylamino)phenyl]-1H-indazol-3-yl]-4-
hydroxy- (CA INDEX NAME)




RN 627859-16-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]-3-methyl-
 (CA INDEX NAME)




RN 627859-17-0 CAPLUS
 CN 1-Piperazinecarboxamide, N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]-4-(2-pyridinyl)- (CA INDEX NAME)




RN 627859-18-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]-4-(phenylmethyl)- (CA INDEX NAME)



RN 627859-19-2 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2-furanylcarbonyl)-N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627859-22-7 CAPLUS
 CN 4-Thiomorpholinecarboxamide, N-[6-(4-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)




RN 627859-24-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]-3-methyl-
(CA INDEX NAME)




RN 627859-26-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]-4-(2-pyridinyl)-
(CA INDEX NAME)




RN 627859-27-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]-4-(phenylmethyl)-
(CA INDEX NAME)




RN 627859-28-3 CAPLUS


CN 1,3-Piperidinedicarboxamide, N3,N3-diethyl-N1-[6-(3-methoxyphenyl)-1H-indazol-3-yl]-
(CA INDEX NAME)




RN 627859-29-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]-3,5-dimethyl- (CA INDEX NAME)




RN 627859-31-8 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-furanylcarbonyl)-N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)



RN 627859-36-3 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[6-(3-methoxyphenyl)-1H-indazol-3-yl]- (CA INDEX NAME)



RN 627859-38-5 CAPLUS
CN 1-Piperidinecarboxamide, 3-methyl-N-[6-(3-thienyl)-1H-indazol-3-yl]- (CA INDEX NAME)



OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2003:719202 CAPLUS

DN 139:246027

TI Preparation of aminoindazoles as protein Tau phosphorylation inhibitors, their drugs and pharmaceutical compositions containing them for treatment,

in particular, of central and peripheral nervous system diseases
 IN Dutruc, Rosset Gilles; Lesuisse, Dominique; Rooney, Thomas; Halley, Franck
 PA Aventis Pharma S. A., Fr.
 SO Fr. Demande, 80 pp.
 CODEN: FRXXBL

DT Patent
 LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2836915	A1	20030912	FR 2002-2997	20020311 <--
	FR 2836915	B1	20080111		
	CA 2478542	A1	20030925	CA 2003-2478542	20030307 <--
	WO 2003078403	A2	20030925	WO 2003-FR752	20030307 <--
	WO 2003078403	A3	20040422		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003242809	A1	20030929	AU 2003-242809	20030307 <--
	AU 2003242809	B2	20100318		
	EP 1487804	A2	20041222	EP 2003-744396	20030307 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003008373	A	20050111	BR 2003-8373	20030307 <--
	CN 1656078	A	20050817	CN 2003-805366	20030307 <--
	JP 2005530711	T	20051013	JP 2003-576409	20030307 <--
	NZ 535147	A	20070831	NZ 2003-535147	20030307
	RU 2345070	C2	20090127	RU 2004-129780	20030307
	US 20040014802	A1	20040122	US 2003-385871	20030311 <--
	US 6949579	B2	20050927		
	MX 2004007478	A	20041110	MX 2004-7478	20040803 <--
	ZA 2004006687	A	20050823	ZA 2004-6687	20040823 <--
	IN 2004CN01977	A	20060224	IN 2004-CN1977	20040903
	IN 224544	A1	20081205		
	HR 2004000824	A2	20050630	HR 2004-824	20040910 <--
	NO 2004004137	A	20041125	NO 2004-4137	20040929 <--
PRAI	FR 2002-2997	A	20020311		
	WO 2003-FR752	W	20030307		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:246027

IT 599192-15-1P, 4-Amino-N-(6-chloro-1H-indazol-3-yl)-1-piperidinecarboxamide 599192-16-2P,


N-(6-Chloro-1H-indazol-3-yl)-4-morpholinecarboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(protein Tau phosphorylation inhibitor; preparation of aminoindazoles as protein Tau phosphorylation inhibitors)

RN 599192-15-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-amino-N-(6-chloro-1H-indazol-3-yl)- (CA INDEX NAME)



RN 599192-16-2 CAPLUS
 CN 4-Morpholinecarboxamide, N-(6-chloro-1H-indazol-3-yl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:610427 CAPLUS
 DN 139:164790
 TI Preparation of indazoles as protein kinase inhibitors
 IN Binch, Hayley; Brenchley, Guy; Golec, Julian M. C.; Knegt, Ronald;
 Mortimore, Michael; Patel, Sanjay; Rutherford, Alistair
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 156 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064397	A1	20030807	WO 2003-US2096	20030123 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2473986	A1	20030807	CA 2003-2473986	20030123 <--
	US 20040009968	A1	20040115	US 2003-350806	20030123 <--
	US 7041687	B2	20060509		
	EP 1467972	A1	20041020	EP 2003-708869	20030123 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005524631	T	20050818	JP 2003-564020	20030123 <--
	CN 1812973	A	20060802	CN 2003-805612	20030123
	AU 2003212833	B2	20080221	AU 2003-212833	20030123
	IL 163117	A	20100531	IL 2003-163117	20030123
	MX 2004007126	A	20050331	MX 2004-7126	20040723 <--
	NO 2004003531	A	20041025	NO 2004-3531	20040824 <--
	NO 328041	B1	20091116		
	JP 2006176530	A	20060706	JP 2006-1918	20060106

AU 2008202214 A1 20080605 AU 2008-202214 20080520
PRAI US 2002-351597P P 20020125
AU 2003-212833 A3 20030123
JP 2003-564020 A3 20030123
WO 2003-US2096 W 20030123

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:164790
IT 574728-46-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of indazoles as protein kinase inhibitors)
RN 574728-46-4 CAPLUS
CN 1H-Tetrazole-1-carboxamide, N-[5-[(4-amino-1-oxo-2-phenylbutyl)amino]-1H-
indazol-3-yl]- (CA INDEX NAME)



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2002:814108 CAPLUS
DN 137:325413
TI Preparation of 1H-indazole derivatives as inhibitors of c-Jun
amino-terminal kinase (JNK)
IN Oinuma, Hitoshi; Ohi, Norihito; Sato, Nobuaki; Soejima, Motohiro; Seshimo,
Hidenori; Terauchi, Taro; Doko, Takashi; Kohmura, Naohiro
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083648	A1	20021024	WO 2002-JP3735	20020415 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440842	A1	20021024	CA 2002-2440842	20020415 <--
AU 2002255263	A1	20021028	AU 2002-255263	20020415 <--
AU 2002255263	B2	20061214		
EP 1380576	A1	20040114	EP 2002-724612	20020415 <--
EP 1380576	B1	20091125		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN	1512987	A	20040714	CN	2002-808290	20020415 <--
CN	1300116	C	20070214			
AT	449763	T	20091215	AT	2002-724612	20020415
US	20040127538	A1	20040701	US	2003-469399	20030828 <--
US	6982274	B2	20060103			
US	20050282880	A1	20051222	US	2005-202234	20050812 <--
US	7541376	B2	20090602			
US	20090203691	A1	20090813	US	2009-426818	20090420
PRAI	JP 2001-116521	A	20010416			
	WO 2002-JP3735	W	20020415			
	US 2003-469399	A3	20030828			
	US 2005-202234	A3	20050812			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:325413


IT 473410-45-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1H-indazole derivs. as inhibitors of c-Jun amino-terminal kinase (JNK) and preventives and/or therapeutics for diseases)

RN 473410-45-6 CAPLUS

CN 4-Morpholinecarboxamide, N-[3-(3-fluorophenyl)-1H-indazol-5-yl]- (CA INDEX NAME)



OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

RE.CNT 131 THERE ARE 131 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:107318 CAPLUS

DN 136:151163

TI Preparation of indazole derivatives as JNK enzyme inhibitors

IN Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.

PA Signal Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 412 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002010137	A2	20020207	WO 2001-US23890	20010730 <--
	WO 2002010137	A3	20020425		
	WO 2002010137	A9	20030206		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,			

RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2417650 A1 20020207 CA 2001-2417650 20010730 <--
 EP 1313711 A2 20030528 EP 2001-957332 20010730 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004513882 T 20040513 JP 2002-516269 20010730 <--
 NZ 524045 A 20040730 NZ 2001-524045 20010730 <--
 AU 2001279089 B2 20060202 AU 2001-279089 20010730
 KR 873541 B1 20081211 KR 2003-701429 20030130
 ZA 2003000886 A 20050309 ZA 2003-886 20030131 <--
 PRAI US 2000-221799P P 20000731
 WO 2001-US23890 W 20010730
 OS MARPAT 136:151163
 IT 395099-94-2P, N-[3-(4-Fluorophenyl)-1H-indazol-5-yl]morpholine-4-
 carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of indazole derivs. as JNK enzyme inhibitors)
 RN 395099-94-2 CAPLUS
 CN 4-Morpholinecarboxamide, N-[3-(4-fluorophenyl)-1H-indazol-5-yl]- (CA
 INDEX NAME)



OSC.G 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2000:911649 CAPLUS
 DN 133:368908
 TI Preparation of heterocyclic piperidines as modulators of chemokine
 receptor activity
 IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III;
 Wacker, Dean A.
 PA Du Pont Pharmaceuticals Co., USA
 SO PCT Int. Appl., 219 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000035877	A1	20000622	WO 1999-XB30314	19991217 <--

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,
 NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 WO 2000035877 A1 20000622 WO 1999-US30314 19991217 <--
 W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,
 NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 US 20020119980 A1 20020829 US 2001-981833 20011018 <--
 US 6759411 B2 20040706
 US 20040186097 A1 20040923 US 2004-809772 20040325 <--
 US 7312222 B2 20071225
 US 20070299057 A9 20071227
 PRAI US 1998-112714P P 19981218
 WO 1999-US30314 19991217
 US 1999-465949 A3 19991217
 US 2001-981833 A3 20011018

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


IT 1122218-88-5 1122218-89-6 1122218-90-9
 1122222-41-6 1122222-42-7 1122222-43-8
 1122223-42-0 1122223-43-1 1122223-44-2
 1122227-96-6 1122227-97-7 1122227-98-8
 1122236-37-6 1122236-38-7 1122236-39-8
 1122238-94-1 1122238-95-2 1122238-96-3
 1122243-87-1 1122243-88-2 1122243-89-3
 1122248-19-4 1122248-20-7 1122248-21-8
 1122258-19-8 1122258-20-1 1122258-21-2
 1122259-16-8 1122259-17-9 1122259-18-0
 1122259-65-7 1122260-91-6 1122260-92-7
 1122265-31-9 1122265-32-0 1122265-33-1

RL: PRPH (Prophetic)

(Preparation of heterocyclic piperidines as modulators of chemokine
 receptor activity)


RN 1122218-88-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[4-[(4-chlorophenyl)methyl]-1-
 piperidinyl)methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122218-89-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[4-[(4-chlorophenyl)methyl]-1-
 piperidinyl)methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122218-90-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122222-41-6 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-3-yl-4-methyl- (CA INDEX NAME)




RN 1122222-42-7 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-5-yl-4-methyl- (CA INDEX NAME)




RN 1122222-43-8 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-6-yl-4-methyl- (CA INDEX NAME)




RN 1122223-42-0 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl-4-methyl- (CA INDEX NAME)




RN 1122223-43-1 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl-4-methyl- (CA INDEX NAME)




RN 1122223-44-2 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl-4-methyl- (CA INDEX NAME)




RN 1122227-96-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122227-97-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122227-98-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122236-37-6 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl-4-methyl- (CA INDEX NAME)




RN 1122236-38-7 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl-4-methyl- (CA INDEX NAME)




RN 1122236-39-8 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl-4-methyl- (CA INDEX NAME)




RN 1122238-94-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122238-95-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122238-96-3 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122243-87-1 CAPLUS

CN 1-Piperazinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl-4-methyl- (CA INDEX NAME)




RN 1122243-88-2 CAPLUS


CN 1-Piperazinecarboxamide, 4-methyl-3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122243-89-3 CAPLUS
 CN 1-Piperazinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl-4-methyl- (CA INDEX NAME)




RN 1122248-19-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122248-20-7 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122248-21-8 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122258-19-8 CAPLUS
 CN 1-Piperazinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl-4-methyl- (CA INDEX NAME)




RN 1122258-20-1 CAPLUS
 CN 1-Piperazinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl-4-methyl- (CA INDEX NAME)




RN 1122258-21-2 CAPLUS
 CN 1-Piperazinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl-4-methyl- (CA INDEX NAME)




RN 1122259-16-8 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122259-17-9 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122259-18-0 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122259-65-7 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122260-91-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122260-92-7 CAPLUS
 CN 1-Piperazinecarboxamide, 4-acetyl-3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122265-31-9 CAPLUS
 CN 1-Piperazinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-3-yl-4-methyl- (CA INDEX NAME)



RN 1122265-32-0 CAPLUS
 CN 1-Piperazinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-5-yl-4-methyl- (CA INDEX NAME)



RN 1122265-33-1 CAPLUS
 CN 1-Piperazinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-6-yl-4-methyl- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2000:911648 CAPLUS
 DN 133:368907
 TI Preparation of heterocyclic piperidines as modulators of chemokine receptor activity
 IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.
 PA Du Pont Pharmaceuticals Co., USA
 SO PCT Int. Appl., 219 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035877	A1	20000622	WO 1999-XA30314	19991217 <--
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000035877	A1	20000622	WO 1999-US30314	19991217 <--
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,				

NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

US	20020119980	A1	20020829	US	2001-981833	20011018 <--
US	6759411	B2	20040706			
US	20040186097	A1	20040923	US	2004-809772	20040325 <--
US	7312222	B2	20071225			
US	20070299057	A9	20071227			
PRAI	US 1998-112714P	P	19981218			
WO	1999-US30314		19991217			
US	1999-465949	A3	19991217			
US	2001-981833	A3	20011018			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


IT	1122159-00-5	1122159-01-6	1122159-02-7
	1122161-64-1	1122161-65-2	1122161-66-3
	1122167-46-7	1122167-47-8	1122167-48-9
	1122169-70-3	1122169-71-4	1122169-73-6
	1122178-50-0	1122178-51-1	1122178-52-2
	1122183-43-0	1122183-44-1	1122183-45-2
	1122185-95-8	1122185-96-9	1122185-97-0
	1122194-39-1	1122194-40-4	1122194-41-5
	1122195-96-3	1122195-97-4	1122195-98-5
	1122198-85-9	1122198-86-0	1122198-88-2
	1122202-77-0	1122202-78-1	1122202-79-2
	1122207-84-4	1122207-85-5	1122207-86-6

RL: PRPH (Prophetic)

(Preparation of heterocyclic piperidines as modulators of chemokine
receptor activity)


RN 1122159-00-5 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[4-[(4-fluorophenyl)methyl]-1-
piperidinyl)methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122159-01-6 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[4-[(4-fluorophenyl)methyl]-1-
piperidinyl)methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122159-02-7 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[4-[(4-fluorophenyl)methyl]-1-
piperidinyl)methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122161-64-1 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122161-65-2 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122161-66-3 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122167-46-7 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122167-47-8 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122167-48-9 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122169-70-3 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122169-71-4 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122169-73-6 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122178-50-0 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122178-51-1 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122178-52-2 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122183-43-0 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122183-44-1 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122183-45-2 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122185-95-8 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122185-96-9 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122185-97-0 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122194-39-1 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122194-40-4 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122194-41-5 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122195-96-3 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122195-97-4 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122195-98-5 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122198-85-9 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122198-86-0 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122198-88-2 CAPLUS

CN 4-Morpholinecarboxamide, 2-[[3-[(4-chlorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122202-77-0 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)




RN 1122202-78-1 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 1122202-79-2 CAPLUS

CN 1-Piperidinecarboxamide, 3-[[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)




RN 1122207-84-4 CAPLUS


CN 4-Morpholinecarboxamide, 2-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-3-yl- (CA INDEX NAME)



RN 1122207-85-5 CAPLUS
CN 4-Morpholinecarboxamide, 2-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-5-yl- (CA INDEX NAME)



RN 1122207-86-6 CAPLUS
CN 4-Morpholinecarboxamide, 2-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-N-1H-indazol-6-yl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT